RxDoctor Payments Data

Geoffrey Onyeukwu, MD

Family Medicine · Gary, INNPI 1093724007

Payments from drug & device makers

$2,959in general payments, 2019–2025

Across 98 payments — averaging $30.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$1K
  • Smith+Nephew$367
  • Organogenesis Inc.$261
  • Mimedx Group, Inc.$192
  • Paratek Pharmaceuticals, Inc.$163
  • Urgo Medical North America, LLC$154
  • plus $704 from 15 others

What the payments were for

  • Speaking & faculty fees$883%
  • Food & beverage$2,87297%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,959 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$44,244
Medicare patients
65
Services billed
516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$29,105
EliquisApixaban12$9,408
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp11$2,884
Levothyroxine Sodium36$1,700
Albuterol Sulfate HfaAlbuterol Sulfate62$1,440
Lidocaine14$927
Atenolol-ChlorthalidoneAtenolol/Chlorthalidone30$648
Nifedipine ErNifedipine22$528
Metronidazole13$490
Duloxetine Hcl53$463
Ibuprofen24$331
Doxazosin Mesylate24$268
Baclofen27$265
Metformin Hcl51$235
Potassium Chloride19$233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24$9,40812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Gary

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →